It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Bacterial heterodimeric tryptophan-containing diketopiperazines (HTDKPs) are a growing family of bioactive natural products. They are challenging to prepare by chemical routes due to the polycyclic and densely functionalized backbone. Through functional characterization and investigation, we herein identify a family of three related HTDKP-forming cytochrome P450s (NasbB, NasS1868 and NasF5053) and reveal four critical residues (Qln65, Ala86, Ser284 and Val288) that control their regio- and stereo-selectivity to generate diverse dimeric DKP frameworks. Engineering these residues can alter the specificities of the enzymes to produce diverse frameworks. Determining the crystal structures (1.70–1.47 Å) of NasF5053 (ligand-free and substrate-bound NasF5053 and its Q65I-A86G and S284A-V288A mutants) and molecular dynamics simulation finally elucidate the specificity-conferring mechanism of these residues. Our results provide a clear molecular and mechanistic basis into this family of HTDKP-forming P450s, laying a solid foundation for rapid access to the molecular diversity of HTDKP frameworks through rational engineering of the P450s.
Bacterial heterodimeric tryptophan-containing diketopiperazines (HTDKPs) are bioactive natural products that are difficult to access chemically. Here, the authors identify a family of three related HTDKP-forming cytochrome P450s and engineer key amino acid residues to produce distinct diketopiperazines frameworks.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Shanghai Jiao Tong University, State Key Laboratory of Microbial Metabolism and School of Life Sciences and Biotechnology, Shanghai, China (GRID:grid.16821.3c) (ISNI:0000 0004 0368 8293); Wuhan University School of Pharmaceutical Sciences, Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, Wuhan, China (GRID:grid.49470.3e) (ISNI:0000 0001 2331 6153)
2 The University of Queensland, School of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, St. Lucia, Australia (GRID:grid.1003.2) (ISNI:0000 0000 9320 7537)
3 Wuhan University School of Pharmaceutical Sciences, Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, Wuhan, China (GRID:grid.49470.3e) (ISNI:0000 0001 2331 6153)
4 Shanghai Jiao Tong University, State Key Laboratory of Microbial Metabolism and School of Life Sciences and Biotechnology, Shanghai, China (GRID:grid.16821.3c) (ISNI:0000 0004 0368 8293)